Understanding your baseline biomarkersmetabolic markers, cardiovascular risk factors, and genetic predispositions in peptide metabolismmay help provide context for why GLP-1 treatment aligns with clinical evidence in your specific case
Thats a big unknown
Eli Lilly have a new, once-monthly GLP1/GIP agonist (Brenipatide) and they're running some fascinating trials with it Smoking cessation, bipolar disorder, schizophrenia, opioid use disorder, depression, alcohol use disorder, and asthma Eli Lilly have a new, once-monthly GLP1/GIP agonist (Brenipatide) and they're running some fascinating trials with it Smoking cessation, bipolar disorder, schizophrenia, opioid use disorder, depression, alcohol use disorder, and asthma That it's dosed monthly probably makes it better suited to psychiatry/addiction settings, where adherence matters a lot I made the table with some inspiration from Lilly's investor deck: investor.lilly.com/static-files/4 interesting stuff
Excess fat tissue increases estrogen levels while reducing testosterone, both of which can impair sperm production
This is because ice crystal formation can disrupt the peptide structure, potentially leading to loss of biological activity or altered properties
.webp?width=850&height=567&name=Hydration%20Room%20Nurse%20Giving%20Patient%20Vitamin%20Injection%20(1).webp)
